WHO boss says vaccine IP waiver not a property ‘snatch’

GENEVA: The World Health Organization on Wednesday sought to reassure pharmaceutical companies that a proposal to suspend patent rights on Covid-19 vaccines was not a bid to “snatch” their intellecutual property rights.

With more than four million dead and the toll likely to reach much higher, WHO Director-General Tedros Adhanom Ghebreyesus said vaccine makers should be offered incentives in return for temporarily waiving their rights.

“Of course, we can’t snatch your property,” Tedros said via video link from Tokyo at the start of a meeting with the World Trade Organization, pharma companies and global financial institutions.

“With so many lives on the line, profits and patents must come second,” he said, without giving any details on the proposed financial incentives.

Waiving intellectual property rights would help meet the 11 billion doses of vaccine the WHO says are needed to protect 70 percent of people in every country by mid-2022.

This is the second meeting in Geneva to try to bridge differences on how to increase supply of jabs and cut the vaccine inequity that sees rich countries eyeing booster shots while health workers in poor countries go without.

Of the 1.1 billion doses produced globally in June, “only 1.4 percent went to Africans, who account for 17 percent of the global population”, WTO Director-General Ngozi Okonjo-Iweal said in her opening speech.

“Only 0.24 percent went to people in low-income countries. And both shares declined even further in the first half of July,” she said.

In addition to the suspension of patents, barriers to the trade in vaccine ingredients must be removed and laboratories agree to transfer their technology, Tedros said.

  • Related Posts

    • Pharma
    • June 23, 2025
    • 115 views
    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    LONDON:  Ananda Pharma PLC (AQSE:ANA, OTCQB: ANANF) has manufactured 40 liters of its lead investigational product MRX1 and 40 liters of matched placebo in compliance with pharmaceutical Good Manufacturing Practices…

    • Pharma
    • June 23, 2025
    • 145 views
    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Hyderabad:  In a ray of hope for HIV patients, particularly for the significant burden in the two-Telugu speaking States of Telangana and Andhra Pradesh, several India pharmaceutical companies have secured…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Drug licences of 9 pharma dealers suspended in Jammu

    Drug licences of 9 pharma dealers suspended in Jammu

    Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

    Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC